Therapeutic effect of the drug of Parkinson`s disease on voiding dysfunction

Therapeutic effect of the drug of Parkinson`s disease on voiding dysfunction - Therapeutic effect of the drug of Parkinson`s disease on voiding dysfunction

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013063

Enrollment

Registered

2014-02-07

Start date

2014-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with voiding dysfunction such as benign prostatic hyperplasia

Interventions

observation period: 4week the drug of Parkinson`s disease is administered for 12 weeks The outcomes is evaluated every 4 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: # international prostate symptom score (IPSS): >8 # QOL score: >4 # voided volume >100ml, Qmax: <15ml # residual volume: <100ml # eligible for coming to the outpatient clinic # stable condition

Exclusion criteria

Exclusion criteria: # neurogenic bladder, bladder neck contracture, urethral stricture, urinary tract infection or other complication # clear intermittent self catheterization # allergic to the drug

Design outcomes

Primary

Measure	Time frame
voiding efficacy (Qmax)	—

Secondary

Measure	Time frame
urinary frequency questionaires for urinary symptom	—

Countries

Japan

Contacts

Public ContactTeruyuki Ogawa

Shinshu University School of Medicine Department of urology

ogawat@shinshu-u.ac.jp0263-37-2661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026